Loading...
Market
Will Novo Nordisk announce a new clinical trial for Ozempic focused on Alzheimer's by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk official announcements and press releases
Story
Novo Nordisk's Ozempic Linked to Significantly Reduced Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 11:08 AM
Novo Nordisk's diabetes medication, Ozempic, has been linked to a significantly reduced risk of Alzheimer's disease, according to a new observational study. The research highlights the drug's potential effects beyond its primary uses for type 2 diabetes and obesity. This finding adds to the growing body of evidence surrounding Ozempic, which is already popular for its benefits in managing diabetes and assisting with weight loss. The study's results are particularly relevant for patients with type 2 diabetes, who may face an increased risk of developing Alzheimer's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
